ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Bacterial Outer Membrane Vesicles in Potentiating Cancer Vaccines: Progress and Prospects.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- New insights into breast cancer therapy: application and mechanisms of novel targeted nano-formulation.International journal of pharmaceutics: X · 2026Review
- Mechanistic Insights and Therapeutic Potential of Plant-Derived Exosome-Like Nanovesicles in Skin Tissue Regeneration.International journal of nanomedicine · 2026Review
- Gut microbiota-host adaptive immune interactions in type 2 diabetes mellitus: mechanisms, disease progression, and microbiota-based therapeutic strategies.Frontiers in microbiology · 2026Review
- Editorial: Research on nanomaterials in tumor diagnosis and therapy, volume II.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Cancer immunotherapy is increasingly moving toward personalized, precision-based strategies, with cancer vaccines emerging as a promising approach to reshape treatment. However, despite their potential, current tumor vaccines often yield limited clinical responses and subpar immunogenicity, underscoring the urgent need for innovative delivery systems to enhance immune activation. Bacterial outer membrane vesicles (OMVs), which possess natural immunomodulatory properties and impressive engineering flexibility, have attracted attention as versatile platforms for vaccine development and bioengineering applications. This review thoroughly summarizes recent advances in using OMVs to enhance the effectiveness of cancer vaccines. First, we explain the key biological features of OMVs that support their immunotherapeutic potential. Next, we carefully analyze the primary mechanisms by which OMVs enhance immune responses, as well as cutting-edge engineering strategies to improve their safety, immunogenicity, and specificity. Additionally, we discuss the significant challenges that hinder the clinical use of OMV-based cancer vaccines and provide a comprehensive review of current progress and future outlooks. Looking forward, combining artificial intelligence, tumor microenvironment profiling, and neoantigen discovery is expected to drive the development of next-generation, personalized OMV-based immunotherapies. Overall, OMVs stand out as a transformative platform capable of overcoming major obstacles in cancer vaccine development and pushing forward future cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.